Ronan J. Kelly, MD, MBA, FASCO

Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.

Ronan J. Kelly, MD, expanded on data from the phase 3 CheckMate 577 study of adjuvant nivolumab following CRT in resected esophageal and GEJ cancer.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.

Ronan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.

Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).